To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.

This bill requires the Food and Drug Administration (FDA) to report to Congress on barriers to the domestic manufacturing of imported active pharmaceutical ingredients, finished drug products, and devices that are critical to public health.

The report must recommend strategies to overcome such barriers. The FDA may, to the extent appropriate, implement the strategies.

Bill 117 hr 6710, also known as the "Domestic Manufacturing and Regulatory Barriers Report Act," aims to address the challenges faced by domestic manufacturers of active pharmaceutical ingredients, finished drug products, and devices. The bill directs the Secretary of Health and Human Services, specifically through the Commissioner of Food and Drugs, to submit a report to Congress detailing the barriers hindering domestic manufacturing in these industries.

The report will specifically focus on regulatory inefficiencies that impede the ability of domestic manufacturers to compete in the global market. By identifying and addressing these barriers, the goal is to promote and support the growth of domestic manufacturing in the pharmaceutical and medical device sectors.

In addition to analyzing regulatory obstacles, the bill also aims to explore other factors that may be contributing to the decline in domestic manufacturing, such as supply chain vulnerabilities and reliance on foreign sources for critical medical products. Overall, the purpose of Bill 117 hr 6710 is to provide Congress with a comprehensive understanding of the challenges faced by domestic manufacturers in the pharmaceutical and medical device industries, in order to inform potential policy solutions that can support and strengthen domestic manufacturing capabilities.